Search results
Results From The WOW.Com Content Network
Current medications used to treat anxiety do not work for everyone. A new study has identified a specific microbial metabolite in the gut microbiome that helps regulate brain activity linked to ...
The Spectrum editorial team founded The Transmitter to expand the publication's neuroscience coverage beyond the autism field; autism stories are covered on The Transmitter within a dedicated Spectrum vertical. [6] Like its predecessor, The Transmitter is funded by the Simons Foundation but maintains editorial independence.
It was like a lightbulb flipping on, she said. The Flathead High School graduate had harbored an interest in neuroscience for years, beginning with a car wreck on Lookout Pass in 1997 that left ...
Today, the most commonly used drug to combat this disease is levodopa or L-DOPA. This precursor to dopamine can penetrate through the blood–brain barrier, whereas the neurotransmitter dopamine cannot. There has been extensive research to determine whether L-dopa is a better treatment for Parkinson's disease rather than other dopamine agonists.
Andrew David Huberman (born September 26, 1975) is an American neuroscientist and podcaster.He is an associate professor of neurobiology and ophthalmology at the Stanford University School of Medicine.
For premium support please call: 800-290-4726 more ways to reach us
David Eagleman (born April 25, 1971) is an American neuroscientist, author, and science communicator.He teaches neuroscience at Stanford University [1] and is CEO and co-founder of Neosensory, a company that develops devices for sensory substitution. [2]
Suzuki's research career started with studying underlying memory. Her lab focused on the role of the hippocampus, which is the part of the brain that is responsible for memory of facts and events, otherwise known as declarative or explicit memory. Her research group was the first to identify major changes to patterns of neural activity in the ...